- Home
- NVNI vs CVKD Comparison
NVNI vs CVKD Comparison
Compare NVNI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- CVKD
- Stock Information
- Founded
- NVNI 2019
- CVKD 2022
- Country
- NVNI Brazil
- CVKD United States
- Employees
- NVNI N/A
- CVKD N/A
- Industry
- NVNI
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- NVNI
- CVKD Health Care
- Exchange
- NVNI Nasdaq
- CVKD Nasdaq
- Market Cap
- NVNI 31.5M
- CVKD 29.5M
- IPO Year
- NVNI N/A
- CVKD 2023
- Fundamental
- Price
- NVNI $0.53
- CVKD $10.86
- Analyst Decision
- NVNI
- CVKD Strong Buy
- Analyst Count
- NVNI 0
- CVKD 1
- Target Price
- NVNI N/A
- CVKD $32.00
- AVG Volume (30 Days)
- NVNI 11.7M
- CVKD 28.9K
- Earning Date
- NVNI 08-12-2025
- CVKD 08-06-2025
- Dividend Yield
- NVNI N/A
- CVKD N/A
- EPS Growth
- NVNI N/A
- CVKD N/A
- EPS
- NVNI N/A
- CVKD N/A
- Revenue
- NVNI $31,250,627.00
- CVKD N/A
- Revenue This Year
- NVNI $12.05
- CVKD N/A
- Revenue Next Year
- NVNI $15.02
- CVKD N/A
- P/E Ratio
- NVNI N/A
- CVKD N/A
- Revenue Growth
- NVNI 1491.58
- CVKD N/A
- 52 Week Low
- NVNI $0.14
- CVKD $5.70
- 52 Week High
- NVNI $12.19
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- NVNI 75.33
- CVKD 38.21
- Support Level
- NVNI $0.35
- CVKD $11.25
- Resistance Level
- NVNI $0.44
- CVKD $11.88
- Average True Range (ATR)
- NVNI 0.07
- CVKD 0.76
- MACD
- NVNI 0.03
- CVKD -0.02
- Stochastic Oscillator
- NVNI 64.12
- CVKD 7.46
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.